Please assess the completion status of the following clinical trial:

Trial Title: A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is 21 years of age or older~* Subject is either not of childbearing potential OR subject must use an acceptable method of birth control if of childbearing potential~* Negative pregnancy test if female of childbearing potential~* Subject is in general good health~* Subject required treatment of joint pain within the last 90 days~* Subject has primary diagnosis of osteoarthritis (OA) of the hip or knee~Exclusion Criteria:~* Subject has a documented history of allergic reaction or intolerance to morphine or other opioids~* Subject is pregnant or breast-feeding~* Subject is receiving systemic chemotherapy~* Subject has a history of drug abuse/dependence/misuse or alcohol abuse/dependence~* Subject has history of major depressive disorder not controlled with medication~* Subject has any chronic pain syndrome (i.e., fibromyalgia) that may interfere with the symptoms of OA~* Subject has active gastrointestinal disease, with the exception of gastroesophageal reflux disease (GERD)~* Subject has a documented history of rheumatoid arthritis, uncontrolled inflammatory arthritis or non-steroidal anti-inflammatory drug (NSAID)-dependent inflammatory arthritis

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALO-01 (Type: EXPERIMENTAL): Up to 80 mg twice a day (bid)
- Placebo (Type: PLACEBO_COMPARATOR): Twice a day (bid)

Based on this trial design, predict the completion outcome and termination type (if applicable).